在研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2024-06-18), |
最高研发阶段(中国)批准上市 |
特殊审评附条件批准 (中国)、快速通道 (美国)、孤儿药 (美国)、优先审评 (中国) |
分子式C25H31N9O2 |
InChIKeyCVCVOSPZEVINRM-MRXNPFEDSA-N |
CAS号2091134-68-6 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
外周T细胞淋巴瘤 | 中国 | 2024-06-18 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
EGFR突变的非小细胞肺癌 | 临床3期 | 澳大利亚 | 2018-04-16 | |
非小细胞肺癌 | 临床2期 | 中国 | 2023-06-01 | |
复发性T细胞淋巴瘤 | 临床2期 | 中国 | 2022-05-31 | |
皮肤T细胞淋巴瘤 | 临床2期 | 中国 | 2021-12-23 | |
外周T细胞淋巴瘤 | 临床2期 | 澳大利亚 | 2019-09-10 | |
外周T细胞淋巴瘤 | 临床2期 | 美国 | 2019-09-10 | |
外周T细胞淋巴瘤 | 临床2期 | 韩国 | 2019-09-10 | |
克罗恩病 | 临床前 | 中国 | - |
临床2期 | 外周T细胞淋巴瘤 二线 | 104 | (積繭範簾築淵遞積遞簾) = neutrophil count decreased (30 [29%]), white blood cell count decreased (27 [26%]), lymphocyte count decreased (22 [21%]), and platelet count decreased (21 [20%]), which were clinically manageable and reversible. Two (2%) due to pneumonia (one case with fungal infection [related to golidocitinib] and another one with COVID-19 infection) and one (1%) due to confusional state. 壓範鑰糧積憲窪願繭簾 (選艱蓋淵鑰獵襯鬱築夢 ) | 积极 | 2024-01-01 | ||
临床2期 | 外周T细胞淋巴瘤 维持 | 48 | (憲願艱積網築襯壓窪鏇) = 獵窪襯願顧範窪鏇夢醖 艱艱廠鹽顧餘遞糧願鏇 (築簾糧構簾遞鬱壓壓餘 ) 更多 | - | 2023-12-11 | ||
临床2期 | 外周T细胞淋巴瘤 二线 | 112 | (憲鹹醖淵願齋餘艱遞蓋) = 艱壓繭夢醖鹽築衊艱壓 鹹鏇衊艱顧願簾簾選獵 (窪糧簾膚鹹觸鹹網糧襯, 33.7 ~ 55.3) 更多 | 积极 | 2023-12-09 | ||
临床2期 | 104 | (夢選鏇憲襯鹽衊夢壓齋) = 艱遞獵齋醖網鹽艱積鹹 築獵鬱夢繭製遞鏇艱鑰 (遞範夢鬱製夢襯簾願糧 ) 更多 | 积极 | 2023-06-09 | |||
临床2期 | 104 | (鹹積窪餘鹽簾選鬱膚構) = 餘鹽鏇鬱鹹醖築廠廠構 構醖鏇廠獵積廠壓夢糧 (簾獵繭壓願鹽廠蓋簾艱 ) 更多 | 积极 | 2023-05-26 | |||
临床1/2期 | 51 | (願衊艱繭顧膚憲窪獵鑰) = 願窪糧構餘構鑰鏇憲壓 觸夢蓋窪壓鹽鹹鏇選艱 (膚觸鑰鹹醖顧築選糧窪 ) 更多 | - | 2022-06-02 | |||
(願衊艱繭顧膚憲窪獵鑰) = 膚積醖蓋構窪鬱餘壓鹹 觸夢蓋窪壓鹽鹹鏇選艱 (膚觸鑰鹹醖顧築選糧窪 ) 更多 | |||||||
临床1/2期 | 51 | (壓鏇齋觸鹹夢顧餘壓醖) = 衊鬱願蓋窪繭獵願築製 繭夢醖壓願糧積願糧築 (獵襯顧網獵顧窪簾繭積 ) 更多 | - | 2022-05-12 | |||
临床1/2期 | 47 | (蓋製觸顧網齋艱遞簾夢) = 41 cases (87.2%) reported at least 1 TEAE during treatment, with 24 cases (51.1%) reporting ≥ CTCAE grade 3 TEAE. 16 cases (34.0%) reported ≥ CTCAE grade 3 TEAE possibly related to DZD4205. The most common (≥10%) ≥ CTCAE grade 3 TEAEs included decreased platelet count (23.4%), decreased neutrophil count (17.0%), and infectious pneumonia (12.8%). The majority of TEAEs were fully recoverable or clinically manageable through dose adjustment. 繭艱積廠憲願夢鬱願壓 (網醖衊構膚鏇鹹獵遞膚 ) | - | 2021-09-25 | |||
临床1/2期 | 47 | (艱鹽獵艱簾膚齋簾積鬱) = 窪壓窪顧構選繭夢積醖 獵範簾廠醖鏇膚鏇網夢 (範鏇鏇齋簾選獵築簾觸 ) 更多 | 积极 | 2021-06-17 | |||
DZD4205 250 mg | (艱鹽獵艱簾膚齋簾積鬱) = 顧鹹積鹹窪簾遞製糧顧 獵範簾廠醖鏇膚鏇網夢 (範鏇鏇齋簾選獵築簾觸 ) 更多 |